| Drug Name: | Primidone (125-33-7) |
|---|---|
| PubChem ID: | 4909 |
| SMILES: | CCC1(C(=O)NCNC1=O)C2=CC=CC=C2 |
| InchiKey: | DQMZLTXERSFNPB-UHFFFAOYSA-N |
| Therapeutic Category: | Anticonvulsants, Central Nervous System Agents |
| Molecular Weight (dalton) | : | 218.256 |
| LogP | : | 0.5379 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 58.2 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Acetazolamide (59-66-5) | Osteomalacia | Antagonistic | Acetazolamide-induced interference with primidone absorption Case reports and metabolic studies | |
| Carbamazepine (298-46-4) | Reduce The Effects Of Carbamazepine | Antagonistic | When the primidone was stopped in the single case cited, the clearance of the carbamazepine decreased by about 60%. This is consistent with the known enzyme-inducing effects ofprimidone (converted in the body to phenobarbital), which can increase the metabolism of other drugs by the liver | Primidone-carbamazepine interaction: clinical consequences |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Hhepatic Cirrhosis | Alanine aminotransferase (P24298) | Hepatic cirrhosis [ ADR Type 2 ] | Hepatic cirrhosis associated with long-term primidone therapy in a dog |
| Hyperbilirubinemia | Alanine aminotransferase (P24298) | Increased activities of Alanine aminotransferase@ alkaline phosphatase (AP)@ and gamma-glutamyltransferase@leading to clinical jaundice and developed hyperbilirubinemia@ delayed sulfobromophthalein excretion@ and increased conjugated bile acid concentrations. [ ADR Type 1 ] | Comparison of rosaramicin and erythromycin stearate for treatment of cervical infection with Chlamydia trachomatis |
| Hyperbilirubinemia | Alkaline phosphatase (P05186) | Increased activities of Alanine aminotransferase@ alkaline phosphatase (AP)@ and gamma-glutamyltransferase@leading to clinical jaundice and developed hyperbilirubinemia@ delayed sulfobromophthalein excretion@ and increased conjugated bile acid concentrations. [ ADR Type 1 ] | Comparison of rosaramicin and erythromycin stearate for treatment of cervical infection with Chlamydia trachomatis |
| Hyperbilirubinemia | Gamma-glutamyltransferase (Q9UJ14) | Increased activities of Alanine aminotransferase@ alkaline phosphatase (AP)@ and gamma-glutamyltransferase@leading to clinical jaundice and developed hyperbilirubinemia@ delayed sulfobromophthalein excretion@ and increased conjugated bile acid concentrations [ ADR Type 1 ] | Comparison of rosaramicin and erythromycin stearate for treatment of cervical infection with Chlamydia trachomatis |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category